Cell Source Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cell Source Inc (CLCS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Cell Source Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cell Source Inc | - | - | - | No |
| Competitors combined (43) | ||||
| High-Confidence Competitors (17) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CLCS Stock Performance relative to its Competitors
CLCS Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Nuvectis Pharma inc | 282.9% | Outperformed |
| 2 | Tango Therapeutics Inc | 282.9% | Outperformed |
| 3 | Apellis Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Kalvista Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Boundless Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cell Source Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Cell Source Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Cell Source Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Cell Source Inc |
23.42 | - |
 United Therapeutics Corporation |
27,173.60 | 3,154.50 |
 Alnylam Pharmaceuticals Inc |
21,623.97 | 5,013.24 |
 Bridgebio Pharma Inc |
15,323.65 | 945.54 |
 Apellis Pharmaceuticals Inc |
5,392.33 | 1,105.28 |
 Tango Therapeutics Inc |
4,322.17 | 66.50 |
| SUBTOTAL | 91,472.58 | 10,436.66 |
Sign in to see all competitors of Cell Source Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cell Source Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cell Source Inc's Competitors Named by the Company
Competitive relationships identified from Cell Source Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Kadmon | Company report | 85% |
| Novartis | Company report | 85% |
| City of Hope | Company report | 85% |
| Incyte | Company report | 85% |
| Merck (OncoImmune) | Company report | 85% |
| Takeda | Company report | 85% |
| Allovir | Company report | 85% |
| Bristol Myers Squibb | Company report | 85% |
| Fred Hutchinson | Company report | 85% |
| Orca | Company report | 85% |
| Abbvie | Company report | 85% |
| Dana Farber | Company report | 85% |
| Johns Hopkins | Company report | 85% |
| Legend | Company report | 85% |
| Atara | Company report | 85% |
| Gilead (KITE) | Company report | 85% |
| Legend | Company report | 85% |
| Allogene | Company report | 85% |
| BMS/Celgene (JUNO) | Company report | 85% |
| Fate | Company report | 85% |
| Bellicum | Company report | 85% |
| Kiadis | Company report | 85% |
| Bluebird | Company report | 85% |
| Molmed | Company report | 85% |
| Cellectis | Company report | 85% |
| Precision | Company report | 85% |
Company report basis, confidence, active dates and source counts for Cell Source Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Cell Source Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Bridgebio Pharma Inc | Reportable 100.00 % |
| Apellis Pharmaceuticals Inc | Reportable Segment Aggregation Before Other Operating Segment 100.00 % |
| Precigen Inc | Reportable 100.00 % |
| Uniqure N v | Single Reportable Segment 100.00 % |
| Intellia Therapeutics Inc | Development of Gene Editing Based Therapies 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Cell Source Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cell Source Inc | 23 | - | -4,719,087 |
| United Therapeutics Corporation | 27,174 | 2,253,214 | 936,357 |
| Alnylam Pharmaceuticals Inc | 21,624 | 2,005,297 | 1,089,696 |
| Bridgebio Pharma Inc | 15,324 | 1,126,985 | -683,899 |
| Apellis Pharmaceuticals Inc | 5,392 | 1,495,643 | 180,337 |
| Tango Therapeutics Inc | 4,322 | 485,401 | -1,518,234 |
| PEERS TOTAL | 91,449 | 1,110,165 | -1,629 |
Cell Source Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| United Therapeutics Corporation | UNITED STATES 97.12 % |
| 23andme Holding Co | United States 90.26 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Cell Source Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 490 companies in Cell Source Inc's industry classification, broader than the peer set above. Market cap in millions of $.Cell Source Inc ranks #0 of 490 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 995, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,278,652 | 24.03 % |
| 2 | Johnson and Johnson | 691,817 | 13.00 % |
| 3 | Abbvie Inc | 521,524 | 9.80 % |
| 4 | Merck and Co Inc | 362,966 | 6.82 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Cell Source Inc | 20 | 0.00 % |
Market cap and industry share for the rest of Cell Source Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-11.
Cell Source Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (447 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.3x | - |
| EV / EBITDA | - | 15.1x | - |
| P/B | -0.8x | 4.2x | -5.1x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -9.73 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cell Source Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cell Source Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 995 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Cell Source Inc's dedicated Suppliers and Customers pages, not here.
Cell Source Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
No rule matched.
Opportunities
- A meaningful share of competitors (59.50 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-34.2% annualized).
Methodology: see Methodology: SWOT Analysis.
Cell Source Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cell Source Inc | 0.01 | 0.03 | - |
| United Therapeutics Corporation | 2.58 | 5.86 | - |
| Alnylam Pharmaceuticals Inc | 1.07 | 2.82 | 0.59 |
| Bridgebio Pharma Inc | 1.23 | 1.74 | - |
| Apellis Pharmaceuticals Inc | 1.58 | 3.49 | 1.36 |
| Tango Therapeutics Inc | 16.66 | 34.00 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cell Source Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cell Source Inc | Q1 2025 | - | - |
| United Therapeutics Corporation | Q2 2026 | -1.9 % | +7.6 % |
| Alnylam Pharmaceuticals Inc | Q3 2026 | +16.7 % | +640.5 % |
| Bridgebio Pharma Inc | Q3 2026 | +192.6 % | - |
| Apellis Pharmaceuticals Inc | Q1 2026 | +60.9 % | - |
| Tango Therapeutics Inc | Q3 2026 | - | - |
| PEERS TOTAL | +24.1 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cell Source Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cell Source Inc | Q1 2025 | - | - |
| United Therapeutics Corporation | Q2 2026 | +13.6 % | +73.6 % |
| Alnylam Pharmaceuticals Inc | Q3 2026 | +83.4 % | +475.1 % |
| Bridgebio Pharma Inc | Q3 2026 | +211.6 % | -89.9 % |
| Apellis Pharmaceuticals Inc | Q1 2026 | -14.5 % | - |
| Tango Therapeutics Inc | Q3 2026 | - | -78.1 % |
Cell Source Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cell Source Inc | - | - | - |
| United Therapeutics Corporation | 17.98% | 19.53% | 20.18% |
| Alnylam Pharmaceuticals Inc | 46.08% | 63.14% | 159.72% |
| Bridgebio Pharma Inc | - | - | - |
| Apellis Pharmaceuticals Inc | 13.20% | 17.94% | 39.71% |
| Tango Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cell Source Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cell Source Inc | - | - |
| United Therapeutics Corporation | 21.30 | 8.61 |
| Alnylam Pharmaceuticals Inc | 8.00 | 4.31 |
| Bridgebio Pharma Inc | - | 16.21 |
| Apellis Pharmaceuticals Inc | 39.45 | 4.88 |
| Tango Therapeutics Inc | - | 64.99 |
| PEERS AVERAGE | - | 8.76 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.